AI Summary
We reviewed 40 live results for vegf inhibitor and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Comparison Table
Recommended
MVASI (bevacizumab-awwb)
Source: Amgen Inc.
Description
MVASI is a recombinant humanized monoclonal antibody that serves as a Vascular Endothelial Growth Factor (VEGF) inhibitor and biosimilar to Avastin. It is provided as a sterile, preservative-free solution for intravenous infusion in 100 mg/4 mL and 400 mg/16 mL single-dose vials. This oncology treatment is indicated for patients with metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma (mRCC), cervical cancer, and various stages of ovarian cancer.
Best for
oncology patients, metastatic colorectal cancer treatment, NSCLC first-line therapy, recurrent glioblastoma management and combination chemotherapy regimens
View Details
Rating
Cosentyx
Source: Novartis Malaysia
Description
Cosentyx (Secukinumab) is an interleukin inhibitor prescribed for plaque psoriasis and psoriatic arthritis. It is supplied as a 150 mg/mL solution for injection in a pre-filled pen or syringe.
Best for
plaque psoriasis, psoriatic arthritis and interleukin inhibition
View Details
Rating
Cosentyx 150mg/ml
Source: Novartis Corporation (Malaysia) Sdn. Bhd.
Description
Secukinumab solution for injection available in a pre-filled pen or pre-filled syringe. This interleukin-17A (IL-17A) inhibitor is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in adults who are candidates for systemic therapy or phototherapy.
Best for
plaque psoriasis patients, psoriatic arthritis management, ankylosing spondylitis treatment and self-injection at home
View Details
Rating
| Compare | MVASI (bevacizumab-awwb) | Cosentyx | Cosentyx 150mg/ml |
|---|---|---|---|
| Source | Amgen Inc. | Novartis Malaysia | Novartis Corporation (Malaysia) Sdn. Bhd. |
| Description | MVASI is a recombinant humanized monoclonal antibody that serves as a Vascular Endothelial Growth Factor (VEGF) inhibitor and biosimilar to Avastin. It is provided as a sterile, preservative-free solution for intravenous infusion in 100 mg/4 mL and 400 mg/16 mL single-dose vials. This oncology treatment is indicated for patients with metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma (mRCC), cervical cancer, and various stages of ovarian cancer. | Cosentyx (Secukinumab) is an interleukin inhibitor prescribed for plaque psoriasis and psoriatic arthritis. It is supplied as a 150 mg/mL solution for injection in a pre-filled pen or syringe. | Secukinumab solution for injection available in a pre-filled pen or pre-filled syringe. This interleukin-17A (IL-17A) inhibitor is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in adults who are candidates for systemic therapy or phototherapy. |
| Best for | oncology patients, metastatic colorectal cancer treatment, NSCLC first-line therapy, recurrent glioblastoma management and combination chemotherapy regimens | plaque psoriasis, psoriatic arthritis and interleukin inhibition | plaque psoriasis patients, psoriatic arthritis management, ankylosing spondylitis treatment and self-injection at home |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"MVASI (bevacizumab-awwb) from Amgen Inc.."
I picked this because MVASI is an FDA-approved biosimilar providing a clinically equivalent therapeutic option for multiple types of advanced and metastatic cancers.
Share this search
Related Finds